LAMIN A/C AND PRELAMINS AS INDICATORS OF FRAILTY AND VULNERABILITY OR RESILIENCY TO ADVERSE HEALTH OUTCOMES
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Dec 25, 2014
app pub date -
Dec 14, 2012
filing date -
Dec 16, 2011
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The present invention provides LMNA gene products as biomarkers for the determination of the vulnerability of an individual to an adverse health outcome when the individual is submitted to a stressor. As herewith provided, a decreased expression of a lamin A/C polypeptide, an increased expression in a lamin precursor polypeptide or a decreased ratio between the lamin A/C polypeptide/lamin precursor polypeptide is observed in individuals who are more vulnerable to an adverse health outcome upon the introduction of a stressor. In some embodiments, these susceptible individuals are considered as frail. The present application provides methods for using this biomarker to assess the risk associated thereto, commercial packages for performing the methods, software products as well as associated systems.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully